ResMed Shares Plummet After Eli Lilly’s Sleep Apnea Trials – Shocking Discovery Sends Stock Prices Crashing!
Sydney, Australia – ResMed, a medical device maker, experienced a significant drop in its shares during intraday trading on Monday. This decline came as a reaction to the results of Phase 3 clinical trials conducted by drugmaker Eli Lilly. The trials revealed the potential effectiveness of one of Eli Lilly’s weight-loss drugs, Zepbound, in reducing the severity of sleep apnea without the need for traditional masks used in treatment. Eli Lilly announced that it has …